{"Symbol": "ONTX", "AssetType": "Common Stock", "Name": "Onconova Therapeutics, Inc", "Description": "Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "375 Pheasant Run, Newtown, PA, United States, 18940", "FullTimeEmployees": "17", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "50263652", "EBITDA": "-20981000", "PERatio": "0.8772", "PEGRatio": "0", "BookValue": "0.09", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-3.814", "RevenuePerShareTTM": "0.002", "ProfitMargin": "0", "OperatingMarginTTM": "-115.8707", "ReturnOnAssetsTTM": "-0.7916", "ReturnOnEquityTTM": "-4.1182", "RevenueTTM": "201000", "GrossProfitTTM": "2183000", "DilutedEPSTTM": "-0.243", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.972", "AnalystTargetPrice": "0.3", "TrailingPE": "0.8772", "ForwardPE": "0", "PriceToSalesRatioTTM": "131.1322", "PriceToBookRatio": "3.2963", "EVToRevenue": "120.9076", "EVToEBITDA": "0", "Beta": "2.6088", "52WeekHigh": "2.84", "52WeekLow": "0.1027", "50DayMovingAverage": "0.9181", "200DayMovingAverage": "0.5486", "SharesOutstanding": "183578000", "SharesFloat": "177964904", "SharesShort": "8560247", "SharesShortPriorMonth": "6369061", "ShortRatio": "0.51", "ShortPercentOutstanding": "0.06", "ShortPercentFloat": "0.0624", "PercentInsiders": "0.913", "PercentInstitutions": "11.158", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:15", "LastSplitDate": "2018-09-26"}